Who
Sally Bridget Lawlor
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Quoin Pharmaceuticals.
In numbers
- Trades disclosed
- 7
- Buys
- 1
- Sells
- 0
- Bought
- $100K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Dec 2025
- Last trade
- 31 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $50K10,244 at $4.88 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,122 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,122 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $50K10,244 at $4.88 | filing |
| 4 Feb 2026filed 6 Feb 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,250 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,250 at $0.00 | filing |
| 1 Dec 2025filed 3 Dec 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,330 at $0.00 | filing |
News
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Raised to "Sell" at Wall Street ZenQNRX · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Sally Bridget Lawlor; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.